NeuroEM Therapeutics is a Phoenix-based medical device company committed to developing, clinically testing, and marketing Transcranial Electromagnetic Treatment (TEMT) as an effective prevention and treatment for Alzheimer’s Disease & other neurodegenerative diseases. We believe our non-invasive bioengineering technology has the potential to prevent, halt, and reverse the memory impairment of Alzheimer’s Disease.
NeuroEM Therapeutics “first-in-class” MemorEM™ device was designed to be comfortably worn on the head to administer TEMT during daily in-home treatment. The electromagnetic waves emanating from multiple emitters in the MemorEM head cap disaggregate toxic protein ‘oligomers’ within neurons throughout the brain. Since these oligomers are increasingly believed to be the root cause of Alzheimer’s Disease, we believe the MemorEM head device will directly attack the Alzheimer’s Disease process. Our pioneering TEMT technology has shown extraordinary promise against AD in all completed preclinical and clinical studies. NeuroEM’s MemorEM head device will be available through neurologists and other health professionals who diagnose memory disorders once we complete our pivotal trial and receive FDA approval.
Management / Advisors
ROBERT MATTHEWS, Ph.D.
Dr. Matthews is an accomplished, hands-on executive with a 23-year track record of leading and driving highly innovative, successful organizations. Rob has raised over $100M in research revenue from government and private investors, founded 5 companies, and developed and brought to market more than 12 products, including 6 medical devices. He is inventor or co-inventor on 20 patents. Rob’s success stems from his ability to analyze an organization’s critical business requirements, identify potential opportunities and risks, and bring together cross-functional high performance teams to develop innovative, cost-effective solutions. He received his Ph.D. in Physics from the University of Western Australia and has a strong background in magnetic and electromagnetic fields.
BILL GORDON, Ph.D.
Dr. Gordon is a scientist turned entrepreneur who trained as a cell biologist, earning a PhD from UC Berkeley for research on cell motility done at Cold Spring Harbor Labs (CSHL) advised by Dr. James Watson. He continued his research as a post-doctoral fellow in Watson’s lab for two years. In 1979, Dr. Gordon’s final year at CSHL, the unofficial focus of the world famous CHSL summer meetings turned to twin technology tsunamis about to hit the world, first the biotechnology wave being led by Genentech and Cetus and second the home computing wave led by Apple. Listening to the debates that summer Dr. Gordon realized he was far more curious about financial markets in biotechnology and home computing, than his research. By 1980, he was programming an Apple II+ to build early computerized trading systems. His quest to understand markets led him to the Wharton School and an MBA in finance. For the next 10 years he served as an officer in two highly successful asset management firms where he focused on markets in new technologies. By 1996, seeing opportunities to wire the world to deliver broadband services, he took the leap as an entrepreneur, co-founding a management company that built “triple play” broadband systems in Spain, France, Germany and Belgium. As CFO he raised $5B in debt and equity to fund a footprint of 24 million franchise homes. In 2002 a successful exit paved the way for two years off devoted to his wife and young sons. In 2005 Dr. Gordon finally returned to science co-founding a biotech company which is currently developing bio-therapeutic non-addictive pain killers to replace opioids. He served as CEO for 6 years before stepping down in 2012 to give back, running accelerator programs and teaching entrepreneurship and social innovation ever since.
GARY. W. ARENDASH, PH.D.
Dr. Arendash was a Full Professor and Research Professor at the University of South Florida for 30 years. During the last 6 years there, he directed the Florida Alzheimer’s Disease Research Center’s Animal Core. Dr. Arendash’s research expertise involves development of therapeutics against Alzheimer’s Disease. He has published over 100 peer-reviewed articles in first tier journals, including Science, Nature and the Journal of Alzheimer’s Disease – the last of which he has held the position of Senior Editor. During his academic career at USF, Dr. Arendash was awarded $5 million in research support from extramural granting agencies, including the National Institutes of Health (NIH) and the Alzheimer’s Disease and Related Disease Association (ADRDA). He was among the very first to provide evidence that Alzheimer’s Disease starts in the brain decades before it is diagnosed. Publication of Dr. Arendash’s landmark study in 2010 providing the first evidence that electromagnetic treatment provides cognitive benefit to Alzheimer’s mice resulted in worldwide interest from the news media. Dr. Arendash is the Founder of NeuroEM Therapeutics and was its CEO through Summer, 2020. As Chief Research Officer, he is now able to focus on the company’s basic and clinical research studies. Dr. Arendash received his Ph.D in Neuroscience/Physiology at the University of California, San Francisco (UCSF). He then did his post-doctoral research at UCLA’s Brain Research Institute prior to joining the faculty at the University of South Florida.
Steve received his MBA in finance from the Wharton School (Univ. of Pennsylvania). He has worked closely with corporate venture/equity groups at GE, ABB, Siemens, Nike and Nielsen, and with funds such as Missionpoint Capital, Lux Capital and Ritchie Capital, while helping early/growth stage companies develop business and capital strategies. Steve is serving or has recently served as an advisor for Tilting Point Media, Mission Critical Services, Le Chao, Fieldview Solutions, Nike, Onvia, Akonni Biosystems, Validus DC Systems, Tiba, The New York Times, Tapergy, C-SAM, Omnex, Dinova, Open Crowd and Nirvana Solutions. His deep business experience and extensive network of C-suite business associates make Steve ideal for leading NeuroEM’s business development.
PATRICIA A. MEAGHER
Patty became a strategic advisor to Dr. Arendash in 2016 focusing primarily on raising seed capital to fund NeuroEM’s initial pilot safety trial. Since then she has worked tirelessly to raise multiple rounds of capital, ramp up the company’s governance, while catalyzing the recruitment of a professional management team to take NeuroEM to the next level. Today she continues her business development efforts as an integral part of the management team now led by Rob Matthews.
Patty is a passionate supporter of entrepreneurs. In 2009 she was noted in Quora as “one of the great women to know in the NYC venture space”. She had just completed what would become a multi-$100M exit, her final deal at Dakota Ventures. In 2010 she immersed herself in the building of Connecticut’s Innovation Ecosystem (CTnext). She founded one of Connecticut’s first Shared Workspace/ Innovation Centers, which launched in early 2012, and was honored with a CT Woman of Innovation nomination. Patty continues to advise/coach high growth IT, BioTech & ‘Green’ Tech startups, and in the past six years her portfolio companies have raised ~$150M. Patty’s career includes 20+ years in Venture Capital, Investment Banking, and Technology, as an Investor, Advisor, & Business Development Professional. She holds a Master’s Degree in Strategy from Wharton.
ROB BARANOWSKI, M.S
5Robert Baranowski is Founder and President of Left Coast Engineering (Escondido, CA). He leads most of the design projects for the company. With more than 25 years of electrical design experience for both military and commercial projects, Rob also has extensive hardware design experience in wireless, power, audio, controllers, location-aware and sensors. His software design and development experience involves user interfaces, drivers and applications. Rob and Left Coast Engineering have designed, tested, and produced the first generation (Gen1) MemorEM head devices utilized by NeuroEM Therapeutics in the company’s Pilot clinical trial. Rob and Left Coast Engineering are currently finalizing the development and initial production of NeuroEM’s Gen 2 MemorEM devices, which will be utilized in all of the company’s future clinical trials. He is an inventor on 20 issued patents, as well as on seven CIP and PCT applications submitted by NeuroEM within the past 1½ years. Previously, Rob was with Sony and Motorola in their cellular design and special projects groups. He holds a Masters of Electrical Engineering from Villanova University. Active in the community, Rob has founded a non-profit instructional baseball program and coaches high school baseball.
MARK A. CUSICK
Mark is co-Founder of MBMC International, PLLC. For many years, he was the Coordinator of the International Practice for a large global law firm. Since moving back to the US from London in 2009 he has worked with entrepreneurs in founding start-ups, provided business consulting, participated in angel investments and served as counsel for select M&A clients.
MARTIN CULJAT, PH.D.
Martin is a medical device veteran, having served as Principal Investigator on 10 NIH, NSF, and DoD-funded programs and published 100+ articles/chapters, both in academia and industry. He has led products through the entire product lifecycle, from early stage product development through clinical trials, FDA clearance, and commercialization. Martin has extensive experience with surgical devices, patient monitoring, medical imaging, and digital medicine, as well as directly related domain experience with pulsed-electromagnetic field (PEMF) devices, neuromodulation devices, and Alzheimer’s disease. He has served as a regulatory consultant and strategic advisor to various digital health, medical device, and pharmaceutical companies. Currently, Martin is Senior VP for Regulatory Innovation & Digital Medicine at EVERSANA.
Board of Directors
John is a full time angel investor and a member of the Clean Energy Venture Group and the Angel Investor Forum. His specific areas of angel investing interest are clean energy, medical devices, and travel. Prior to his second career in angel investing, John spent over 25 years in the low cost airline business. He served as Treasurer and later VP of Operations Planning and Analysis at Southwest Airlines. He was founding EVP and CFO of JetBlue Airways, where, in addition to responsibility for aircraft acquisitions and the finance function, he later added oversight of IT and Supply Chain. He managed the company’s successful IPO in 2002 and negotiated the launch contract for the EMBRAER 190. After departing JetBlue, he served as CFO of Volotea, a Barcelona-based low cost airline, during its formative years during which the company successfully raised 65 million Euros of equity financing.
ROBERT MATTHEWS, Ph.D.
As the CEO of NeuroEM Therapeutics, Dr. Matthews is also serving as a representative of management on the Board of Directors.
Gary W. Arendash, Ph.D.
As Chief Research Officer, Dr. Arendash is also serving as a representative of management on the Board of Directors.
Edward Goodwin, Ph.D.
Dr. Goodwin’s scientific career spans 36 years in bioinformatics, cell, and molecular biology. His patented work from graduate school is still used in the high-level production of many important therapeutics including Rituxan, the number one selling anti-cancer drug. As a fellow and later a faculty member in the Yale Department of Genetics, he used a cervical cancer model system to discover that the genes involved in the very early stages of cancer sensitize tumor cells to treatments that downregulate those genes, a process later popularized as “oncogene addiction”. He also discovered pathways leading tumor cells to spontaneously “age” in a process called induced senescence whereby rapidly growing cells cease proliferation within one day of treatment and adopt the characteristics of normal cells grown to exhaustion over many months of cell culture. His Yale career culminated in the discovery of genes essential for infection by DNA tumor viruses and architecture of the nuclear envelope. As an avid Angel Investor and entrepreneur for the past 10 years, Dr. Goodwin has personally investing in 34 early stage companies and is a past president and current board member of the Angel Investor Forum, Connecticut’s largest Angel Investor group. He continues to advise many companies on topics ranging from fundraising to hard science and business strategy and has twice served as the Chief Technical Officer for Connecticut bioscience companies. He is an active panelist, speaker and judge in the startup community and is often solicited for opinions regarding bioscience investment.
RICHARD LIEBERMAN, JD
Rick is Chairman of Jennings, Strouss & Salmon PLC’s Corporate, Securities and Finance Department in Phoenix. He has extensive experience in a broad range of business law issues, including mergers and acquisitions, securities, corporate governance, finance and banking, executive compensation, bankruptcy, and corporate restructuring. Mr. Lieberman has served as in-house General Counsel and outside counsel to a variety of companies, ranging in size from start-ups to Fortune 500 companies.
Collaborators / Partners
Memorem Device Development
Left Coast Engineering
Senior Engineering Project Lead
RF Exposure Lab
Jay Moulton, Vice-President
David Wittwer, Ph.D.
Richard Ziolkowski, Ph.D.
Eric Knight, President
USF Health/Byrd Alzheimer’s Institute
Amanda Smith MD
Axiom Clinical Research of Florida
Susan Steen, M.D.
Haitham Abulaban, MBBS, CCRC
Gary Wisniewski, Ph.D.
Lino Becerra, M.D.
Basic Science/SBIR Research
MegaNano Biotech Inc.
Chuanhai Cao, Ph.D.
University of South Florida
Dr. Chuanhai Cao, Ph.D.
Ziaopeng Li, Ph.D.
Jing Wang, Ph.D.
Scientific Advisory Board
Huntington Potter, Ph.D.
Dr. Huntington Potter is Professor of Neurology, member of the Linda Crnic Center for Down Syndrome, and Director of the Rocky Mountain Alzheimer’s Disease Center at the University of Colorado Anschutz Medical Campus. He is devoted to studying the mechanistic relationship between Alzheimer’s Disease and Downs syndrome, recognizing that these disorders are two sides of the same coin. Prior to joining UC Denver, Dr. Potter studied, researched and taught for 30 years at Harvard University. He received his AB Cum Laude in Physics and Chemistry and his MA and PhD in Biochemistry and Molecular Biology before spending 13 years on the faculty of the Neurobiology Department. In 1998, Dr. Potter joined the Faculty at the University of South Florida as the Eric Pfeiffer Chair for Research on Alzheimer’s Disease. He designed and directed the NIA-designated Florida Alzheimer’s Disease Research Center at USF and from 2004-2008 he was CEO of the Johnnie B. Byrd Sr. Alzheimer’s Center & Research Institute during this time, the Institute built the largest free-standing Alzheimer’s disease research institute in the world. Dr. Potter discovered that Alzheimer’s disease and Down syndrome, which invariably leads to Alzheimer’s by age 30-40, are mechanistically related to each other through the development of cells with abnormal numbers of chromosomes; this is the focus of his current research at UC Denver. He is author of over 100 scientific articles/books and is the holder of 15 U.S. and foreign patents. In 2010, Dr. Potter was elected a Fellow of the American Association for the Advancement of Science and was selected one of Colorado’s Top Thinkers of 2013 by the Denver Post. His electron micrographs of DNA are on permanent exhibit in the National American History Museum of the Smithsonian Institute in Washington D.C.
Richard Caselli, M.D.
Dr. Caselli is Associate Director and Clinical Core Director of the Alzheimer’s Disease Center at Mayo Clinic in Arizona, which focuses on symptomatic patients with mild cognitive impairment and dementia. He is also a Professor of Neurology at Mayo Clinic’s College of Medicine. Dr. Caselli has served at Mayo’s Scottsdale campus since 1990 and is also recent Past Chairman of Mayo’s Department of Neurology. He holds an adjunct clinical faculty appointment at the Biodesign Institute at Arizona State University, serves as an Adjunct Professor at ASU’s Department of Biomedical Informatics, and currently is a Member of the Advisory Board of the Center for Services Leadership of the W.P. Carey School of Business at ASU. Dr. Caselli also serves on the board of directors of the Arizona Alzheimer’s Consortium. He is certified by the American Board of Electrodiagnostic Medicine, American Board of Neurology and Psychiatry, and National Board of Medical Examiners. Dr. Caselli received both his M.D. and bachelor’s degrees from Columbia University in New York. He served an internship and residency at Mayo Graduate School of Medicine and a fellowship in behavioral neurology and cognitive neuroscience at the University of Iowa College of Medicine. The research program of Dr. Caselli focuses on cognitive aging and the changes that can be detected before the symptomatic onset of memory loss and related symptoms of Alzheimer’s disease. His personal focus is on the neuropsychological and related behavioral changes in AD that can be detected. Through a close series of collaborations, he is also involved in brain imaging (FDG-PET, PIB-PET and MRI), neuropathology, genomics, and epigenetic factors that influence Alzheimer’s disease risk and age of onset.
Ranjan Duara, M.D.
Dr. Duara is the Medical Director of the Wien Center for Alzheimer’s Disease and Memory Disorders at Mount Sinai Medical Center. He is also Associate Director of the University of Florida/Mt. Sinai Alzheimer’s Disease Research Center, and director of its clinical core based at Mount Sinai. Through his work as co-director and clinical core leader of the Florida Alzheimer’s Disease Research Center and principal investigator of the Alzheimer’s Disease Initiative’s Florida Brain Bank, Dr. Duara has helped to enhance what is known about the biology of the disease. In May 2005, Dr Duara and his team, in collaboration with the Johnnie Byrd Alzheimer’s Institute at the University of South Florida in Tampa, received a prestigious grant from the National Institutes of Health (NIH) to become one of 31 Alzheimer’s Disease Research Centers (ADRC) in the U.S to conduct cutting-edge research on Alzheimer’s. Dr. Duara is an Associate Professor of Medicine, Neurology and Psychiatry at the University of Miami School of Medicine. He completed neurology residencies in the United Kingdom and at Thomas Jefferson University Hospital in Philadelphia, and did a fellowship in neuroscience and neuroimaging at the National Institutes of Health. His research has focused primarily on early diagnosis of Alzheimer’s disease and other dementias, neuroimaging, genetic epidemiology, and the methodology for staging the transition from normal cognitive aging to dementia. He has contributed to more than 150 articles in peer-review scientific journals and has been an investigator in numerous clinical trials of novel agents for the treatment of Alzheimer’s Disease. Dr. Duara is also the chair and organizer of the Mild Cognitive Impairment Symposium, which is held annually in Miami Beach.